Investigating the Safety Profile of NanoDNA-LNP Dengue Vaccine against Antibody-Dependent Enhancement of Dengue and Other Flaviviral Infections in Mouse Models.
Anusandhan National Research Foundation [ANRF]
Research Summary
Vaccines are one of the most powerful tools for preventing infectious diseases as well as the
safest way to limit the effects of pandemic and epidemic risks on public health. The covid pandemic
has been a huge inflexion point in vaccine innovation and has facilitated the development of
numerous vaccine technologies to mitigate public health crises. Among other technologies, nucleic
acid vaccines have emerged as a rapid and versatile platform for an emergency. The pandemic also
highlights the need for the importance of viral genome surveillance to tackle viral variants, expand
the number of antigens, and assess diverse delivery systems for vaccines against emerging viruses.
In this context of viral vaccines, the laboratory is interested in 3 major interconnected streams,
Stream 1: Genomic surveillance of emerging/re-emerging viral threats using NGS approaches and
integrating genetic diversity to design innovative vaccine antigen libraries.
Stream 2: Utilizing nucleic acids in viral vaccine development
Stream 3: Investigating human immune responses to vaccines and natural infections using systems
immunology
Current Research Grants
-
2028 2025
-
2028 2025
Identification and Functional Characterization of Novel Short IRES Elements for Effective Circular RNA Translation: An Emerging Platform for Vaccines/Therapeutics.
Anusandhan National Research Foundation [ANRF]
-
2028 2025
Novel Thermostable circular RNA vector for vaccine delivery: Pandemic Preparedness against Emerging Viral Infections
Department of Biotechnology [DBT]
-
2026 2023
Novel Adjuvanted Nano plasmid-based DNA Vaccine Development for Dengue Virus Viruses: Opportunities to Expand the Platform for Emerging Infectious Diseases and One Health
BIRAC-Biotechnology Ignition Grant